

Inter Partes Review in the Life Sciences Industry

May 2019

Partner **David Berl** and associates **Michael Xun Liu** and **Jingyuan Luo** recently co-authored an article for *IAM Life Sciences: Key Issues for Senior Life Sciences Executives 2019* entitled “*Inter Partes* Review in the Life Sciences Industry.” The article covers recent trends in life sciences IPR proceedings and examines the interaction between IPR, Hatch-Waxman, and biosimilar litigation.

[Click here](#) to read the article. To view the IAM Life Sciences guide in full, please go to www.IAM-media.com.